Targeting the glucagon receptor signaling pathway as a novel strategy to counteract PI3K inhibitor induced hyperglycemia while sustaining tumor PI3K inhibition.

Wang, Jie; Osada, Takuya; Morse, Michael A; Calzone, Frank; Yan, Hai; Thai, Dung; Lyerly, H Kim

Wang, Jie; Osada, Takuya; Morse, Michael A; Calzone, Frank; Yan, Hai; Thai, Dung; Lyerly, H Kim.

Afiliación

Wang J; Department of Medicine, Duke Cancer Institute, Durham, NC, USA.
Osada T; Department of Surgery, Duke Cancer Institute, Durham, NC, USA.
Morse MA; Department of Medicine, Duke Cancer Institute, Durham, NC, USA.
Calzone F; ImmPACT-Bio, Camarillo, CA, USA.
Yan H; REMD Biotherapeutics, Camarillo, CA, USA.
Thai D; REMD Biotherapeutics, Camarillo, CA, USA.
Lyerly HK; Department of Surgery, Duke Cancer Institute, Durham, NC, USA.

Leuk Lymphoma ; 62(7): 1761-1764, 2021 07.

Article en En | MEDLINE | ID: mdl-33576297

Asunto(s)

Hiperglucemia; Neoplasias; Glucagón; Humanos; Hiperglucemia/inducido químicamente; Fosfatidilinositol 3-Quinasas/genética; Fosfatidilinositol 3-Quinasas/metabolismo; Receptores de Glucagón/genética; Transducción de Señal

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Hiperglucemia / Neoplasias Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google